Kaiyu Huang, Kaiyu Huang, Yao Wang, Yao Wang, Sijia Sun, Sijia Sun, . . . Xuefeng Xie. (2022). Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China. Frontiers Media S.A..
Chicago Style (17th ed.) CitationKaiyu Huang, et al. Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationKaiyu Huang, et al. Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.